Patent ID: 8604056

Claim:
A compound of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: A is pyrrolidinyl, pyridyl, indazolyl, indolyl, imidazolyl, furanyl, thienyl, benzimidazolyl, benzisoxazolyl, benzothiazolyl, benzothiophenyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, and pyrazolyl each substituted with 0-3 R 2 ; provided that A is not attached to L 1 via any of the nitrogen atoms on the A ring; L 1 is —CH 2 CH 2 —, —CH═CH—, or —CH 2 NH—; M is R 2 is, independently at each occurrence, ═O, F, Cl, Br, OCF 3 , CF 3 , CHF 2 , CN, NO 2 , —(CH 2 ) r OH, —(CH 2 ) r OC 1-4 alkyl, —(CH 2 ) r NH 2 , —(CH 2 ) r NH(C 1-4 alkyl), —(CH 2 ) r N(C 1-4 alkyl) 2 ,—C 1-6 alkyl substituted with 0-1 R 2a , R 2a is F, OCF 3 , CF 3 , R 3 is, independently at each occurrence, phenyl substituted with 0-2 R 3a , naphthyl substituted with 0-2 R 3a , 1,2,3,4-tetrahydro-naphthyl substituted with 0-3 R 3a , or a 5- to 12-membered heterocycle comprising: carbon atoms and 1-2 heteroatoms selected from N, O, and S(O) p , wherein said heterocycle is substituted with 0-2 R 3a ; R 3a is, independently at each occurrence, ═O, F, Cl, Br, Me, CN, OH, OMe, —OC(O)(t-Bu), CH 2 OMe, CF 3 , COMe, CO 2 H, CO 2 Me, —CH 2 CO 2 H, —(CH 2 ) 2 CO 2 H, —CH 2 CO 2 Me, —CH 2 CO 2 Et, —CH 2 CH 2 CO 2 Et, —CH 2 CN, NH 2 , —CH 2 NH 2 , —CH 2 NMe 2 , —NHCOMe, —NHCO 2 Me, —NHCO 2 Et, —NHCH 2 CH 2 CO 2 H, —NHCO 2 (i-Pr), —NHCO 2 (i-Bu), —NHCO 2 (t-Bu), —NHCO 2 Bn, —NHCO 2 CH 2 CH 2 OMe, —NHCO 2 CH 2 CH 2 CH 2 OMe, —NHCO 2 CH 2 CO 2 H, —NHCO 2 CH 2 CH 2 CO 2 H, —NHCO 2 CH 2 CH 2 OH, —NHCO 2 CH 2 CH 2 NH 2 , —NHCO 2 CH 2 -tetrahydrofuran-2-yl, —NHCO 2 CH 2 CH 2 CH(Me)OMe, —NHCO 2 CH 2 CH 2 C(O)NH 2 , —NHC(O)NHCH 2 CH 2 -morpholino, —NHC(O)NHCH 2 -pyrid-4-yl, —NHCO 2 CH 2 -pyrid-4-yl, —NHCO 2 CH 2 -pyrid-3-yl, —NHCO 2 CH 2 -pyrid-2-yl, —NHCO 2 CH 2 -(piperidin-4-yl), —NHC(O)NHCH 2 CH 2 -pyrid-4-yl, —NHCO 2 CH 2 CH 2 -pyrid-4-yl, —NHCO 2 CH 2 CH 2 -morpholino, —CH 2 NHCO 2 Me, —NHC(O)NHMe, —NHC(O)N(Me) 2 , —NHC(O)NHCH 2 CH 2 OMe, 4-[(1-carbamoyl-cyclopropanecarbonyl)-amino]-, —NHSO 2 Me, —SO 2 NH 2 , —SO 2 NHMe, —SO 2 NHCH 2 CH 2 OH, —SO 2 NHCH 2 CH 2 OMe, —CONH 2 , —CONHMe, —CON(Me) 2 , —C(O)NHCH 2 CH 2 OMe, —CH 2 CONH 2 , —CO(N-morpholino), —NHCH 2 CH 2 (N-morpholino), —NH(1H-imidazol-2-yl), 1H-tetrazol-5-yl, tetrazol-1-yl, pyrimidin-5-yl, or N-morpholino; R 4 is, independently at each occurrence, H, F, Cl, Br, OMe, NH 2 , CF 3 , Me, Et, CO 2 H, CO 2 Me or CO 2 Et; R 8a is H or C 1-4 alkyl; R 11 is —(CH 2 ) r -phenyl substituted with 0-2 R 11b , —(CH 2 ) r -indanyl substituted with 0-2 R 11b , —(CH 2 ) r -indenyl substituted with 0-2 R 11b , —(CH 2 ) r -naphthyl substituted with 0-2 R 11b ; R 11b is, independently at each occurrence, H, ═O, F, Cl, Br, CF 3 , OH, OMe, OEt, —CH 2 OH, —C(CH 3 ) 2 OH, —CH 2 OMe, O(i-Pr), OCF 3 , OCHF 2 , CN, OPh, OBn, NO 2 , NH 2 , C 1-6 alkyl; —(CH 2 ) r —C 3-10 carbocycle substituted with 0-3 R 11b , r, at each occurrence, is selected from 0, 1, 2, 3, and 4.